SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

By El-Khoueiry Anthony  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1646-1651

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

By Faris Jason  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1614-1620

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

By Goldstein D.   Ackland S.   Bell D.   Olver I.   Davis I.   Rosenthal M.   Toner G.   Pinel M.   Byrne M.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 429-434

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

By Bruce Justine  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 794-802

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By Garcia Jorge A.   Hudes Gary R.   Choueiri Toni K.   Stadler Walter M.   Wood Laura S.   Gurtler Jayne   Bhatia Shailender   Joshi Adarsh   Hozak Rebecca R.   Xu Yihuan   Schwartz Jonathan D.   Thompson John A.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

Blackwell Publishing

Access to resources Recommend Favorite